Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Bernardi

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 16, 2017
A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell TransplantationAlessandra Forcina, Paola M V Rancoita, Magda Marcatti, et al.
Frontiers in Oncology|July 9, 2024
Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experienceElisa Diral, Giulia Furnari, Alessandro Bruno, et al.
American Journal of Hematology|June 21, 2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioningAvichai Shimoni, Luca Vago, Massimo Bernardi, et al.
Frontiers in Oncology|July 5, 2022
Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell TransplantationFabio Giglio, Elisabetta Xue, Raffaella Greco, et al.
Hematological Oncology|December 4, 2014
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosisSimone Claudiani, Sarah Marktel, Simona Piemontese, et al.
Frontiers in Immunology|October 22, 2019
Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant CyclophosphamideRaffaella Greco, Francesca Lorentino, Rosamaria Nitti, et al.
Annals of Hematology|July 17, 2018
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda networkPatrizia Zappasodi, Laura Marbello, Erika Borlenghi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2020
Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA MatchingChiara Oltolini, Raffaella Greco, Laura Galli, et al.
Frontiers in Immunology|February 9, 2024
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohortElisa Diral, Corrado Campochiaro, Alessandro Tomelleri, et al.
Leukemia & Lymphoma|April 10, 2008
Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantationRoberto Crocchiolo, Carla Canevari, Andrea Assanelli, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 16, 2017
A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell TransplantationAlessandra Forcina, Paola M V Rancoita, Magda Marcatti, et al.
Frontiers in Oncology|July 9, 2024
Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experienceElisa Diral, Giulia Furnari, Alessandro Bruno, et al.
American Journal of Hematology|June 21, 2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioningAvichai Shimoni, Luca Vago, Massimo Bernardi, et al.
Frontiers in Oncology|July 5, 2022
Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell TransplantationFabio Giglio, Elisabetta Xue, Raffaella Greco, et al.
Hematological Oncology|December 4, 2014
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosisSimone Claudiani, Sarah Marktel, Simona Piemontese, et al.
Frontiers in Immunology|October 22, 2019
Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant CyclophosphamideRaffaella Greco, Francesca Lorentino, Rosamaria Nitti, et al.
Annals of Hematology|July 17, 2018
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda networkPatrizia Zappasodi, Laura Marbello, Erika Borlenghi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2020
Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA MatchingChiara Oltolini, Raffaella Greco, Laura Galli, et al.
Frontiers in Immunology|February 9, 2024
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohortElisa Diral, Corrado Campochiaro, Alessandro Tomelleri, et al.
Leukemia & Lymphoma|April 10, 2008
Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantationRoberto Crocchiolo, Carla Canevari, Andrea Assanelli, et al.
Pageof 10